Drug Profile
Research programme: macrolide antibacterials - Isomerase Therapeutics/Pfizer
Latest Information Update: 06 Jun 2007
Price :
$50
*
At a glance
- Originator Biotica Technology; Pfizer
- Class
- Mechanism of Action Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 06 Jun 2007 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)